Joel Hanhart1, Doron S Comaneshter2, Yossi Freier-Dror3, Shlomo Vinker2,4. 1. Department of Ophthalmology, Shaare Zedek Medical Center, 12 Beyt Street, 91031, Jerusalem, Israel. hanhart@szmc.org.il. 2. Central Headquarters, Clalit Health Services, Tel Aviv, Israel. 3. Mashav Applied Research, Jerusalem, Israel. 4. Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel.
Abstract
BACKGROUND: Intraocular injections of antivascular endothelial growth factor (VEGF) agents are currently the main therapy in age-related macular degeneration (AMD). The safety of bevacizumab, an anti-VEGF compound frequently delivered off label, is debated, particularly for high-group risks. We aim to analyze the mortality associated with intravitreal injections of bevacizumab for AMD in patients previously diagnosed with acute myocardial infarct (MI). METHODS: In a national database, we identified bevacizumab-treated AMD patients with a diagnosis of MI prior to their first bevacizumab injection, delivered between September 2008 and October 2014 (n = 2100). We then generated sub-groups of patients treated within 3 months (n = 11), 6 months (n = 24), 12 months (n = 52), and 24 months (n = 124) after MI. Those patients were compared to age- and gender-matched members that had a MI at the same time and had never been exposed to anti-VEGF. Survival analysis was performed using propensity score-adjusted Cox regression. RESULTS: Bevacizumab-treated patients were slightly and insignificantly older than controls (mean age 83.25 vs 83.19 year, P = .75). Gender distribution was similar. In a Cox regression adjusted with propensity score, the following differences in mortality were found: within 3 months between MI and initiation of bevacizumab treatment, OR = 6.22 (95% C.I 1.08-35.97, P < .05); within 6 months, OR = 2.37 (95% C.I 0.93-6.02, P = .071); within 12 months, OR = 3.00 (95% C.I 1.44-6.28, P < .01); within 24 months after MI, OR = 2.24 (95% C.I 1.35-3.70, P < .01); and MI any time prior to first bevacizumab injection, OR = 1.71 (95% C.I 1.53-1.92, P < .001). CONCLUSIONS: We report increased mortality associated with the use of intravitreal bevacizumab in AMD patients after MI, compared to age- and gender-matched post-MI patients with no exposure to any anti-VEGF agent. Caution should be taken while offering bevacizumab to AMD patients after MI.
BACKGROUND: Intraocular injections of antivascular endothelial growth factor (VEGF) agents are currently the main therapy in age-related macular degeneration (AMD). The safety of bevacizumab, an anti-VEGF compound frequently delivered off label, is debated, particularly for high-group risks. We aim to analyze the mortality associated with intravitreal injections of bevacizumab for AMD in patients previously diagnosed with acute myocardial infarct (MI). METHODS: In a national database, we identified bevacizumab-treated AMDpatients with a diagnosis of MI prior to their first bevacizumab injection, delivered between September 2008 and October 2014 (n = 2100). We then generated sub-groups of patients treated within 3 months (n = 11), 6 months (n = 24), 12 months (n = 52), and 24 months (n = 124) after MI. Those patients were compared to age- and gender-matched members that had a MI at the same time and had never been exposed to anti-VEGF. Survival analysis was performed using propensity score-adjusted Cox regression. RESULTS:Bevacizumab-treated patients were slightly and insignificantly older than controls (mean age 83.25 vs 83.19 year, P = .75). Gender distribution was similar. In a Cox regression adjusted with propensity score, the following differences in mortality were found: within 3 months between MI and initiation of bevacizumab treatment, OR = 6.22 (95% C.I 1.08-35.97, P < .05); within 6 months, OR = 2.37 (95% C.I 0.93-6.02, P = .071); within 12 months, OR = 3.00 (95% C.I 1.44-6.28, P < .01); within 24 months after MI, OR = 2.24 (95% C.I 1.35-3.70, P < .01); and MI any time prior to first bevacizumab injection, OR = 1.71 (95% C.I 1.53-1.92, P < .001). CONCLUSIONS: We report increased mortality associated with the use of intravitreal bevacizumab in AMDpatients after MI, compared to age- and gender-matched post-MI patients with no exposure to any anti-VEGF agent. Caution should be taken while offering bevacizumab to AMDpatients after MI.
Authors: H Brønnum-Hansen; T Jørgensen; M Davidsen; M Madsen; M Osler; L U Gerdes; M Schroll Journal: J Clin Epidemiol Date: 2001-12 Impact factor: 6.437
Authors: Karen A Hicks; James E Tcheng; Biykem Bozkurt; Bernard R Chaitman; Donald E Cutlip; Andrew Farb; Gregg C Fonarow; Jeffrey P Jacobs; Michael R Jaff; Judith H Lichtman; Marian C Limacher; Kenneth W Mahaffey; Roxana Mehran; Steven E Nissen; Eric E Smith; Shari L Targum Journal: Circulation Date: 2014-12-29 Impact factor: 29.690
Authors: Y Hojo; U Ikeda; Y Zhu; M Okada; S Ueno; H Arakawa; H Fujikawa; T Katsuki; K Shimada Journal: J Am Coll Cardiol Date: 2000-03-15 Impact factor: 24.094
Authors: Ryan M Rich; Philip J Rosenfeld; Carmen A Puliafito; Sander R Dubovy; Janet L Davis; Harry W Flynn; Serafin Gonzalez; William J Feuer; Richard C Lin; Geeta A Lalwani; Jackie K Nguyen; Gaurav Kumar Journal: Retina Date: 2006 May-Jun Impact factor: 4.256
Authors: M L Subramanian; G Abedi; S Ness; E Ahmed; M Fenberg; M K Daly; A Houranieh; E B Feinberg Journal: Eye (Lond) Date: 2010-10-01 Impact factor: 3.775
Authors: Robert L Avery; Alessandro A Castellarin; Nathan C Steinle; Dilsher S Dhoot; Dante Joseph Pieramici; Robert See; Stephen Couvillion; Ma'an A Nasir; Melvin D Rabena; Kha Le; Mauricio Maia; Jennifer E Visich Journal: Br J Ophthalmol Date: 2014-07-07 Impact factor: 4.638
Authors: Janusz Blasiak; Cezary Watala; Raimo Tuuminen; Niko Kivinen; Ali Koskela; Hannele Uusitalo-Järvinen; Anja Tuulonen; Mateusz Winiarczyk; Jerzy Mackiewicz; Szymon Zmorzyński; Agata Filip; Kai Kaarniranta Journal: J Cell Mol Med Date: 2019-10-21 Impact factor: 5.310
Authors: Shan Liu; Antje K Biesemeier; Alexander V Tschulakow; Harsh V Thakkar; Sylvie Julien-Schraermeyer; Ulrich Schraermeyer Journal: Biol Open Date: 2020-06-11 Impact factor: 2.422
Authors: B Sobolewska; B Fehrenbacher; P Münzer; H Kalbacher; S Geue; Konstantinos Stellos; M Schaller; F Ziemssen Journal: J Ophthalmol Date: 2021-06-14 Impact factor: 1.909